Phase II trial: melatonin oral gel for prevention of mucositis in oropharynx and oral cavity tumors

被引：1

作者：

Lozano Borbalas, A. ^{[1
]}

Marruecos, J. ^{[2
]}

Rubio-Casadevall, J. ^{[3
]}

Farre, N. ^{[4
]}

Lopez-Pousa, A. ^{[5
]}

Gomez-Millan, J. ^{[6
]}

Toledo, M. D. ^{[6
]}

Morera, R. ^{[7
]}

Glaria, L. ^{[7
]}

Planas, I. ^{[8
]}

Mesia, R. ^{[9
]}

Lanzuela, M. ^{[10
]}

Giralt, J. ^{[11
]}

Cascallar, L. ^{[12
]}

Vazquez Masedo, G. ^{[13
]}

Valenti, V. ^{[14
]}

Ortiz, J. ^{[15
]}

Grima, P. ^{[15
]}

Tarrago, C. ^{[15
]}

Bosser, R. ^{[15
]}

机构：

[1] Inst Catala Oncol, Radiat Oncol, Lhospitalet De Llobregat, Spain

[2] Inst Catala Oncol, Radiat Oncol, Girona, Spain

[3] Inst Catala Oncol, Med Oncol, Girona, Spain

[4] Hosp Santa Creu & Sant Pau, Radiat Oncol, Barcelona, Spain

[5] Hosp Santa Creu & Sant Pau, Med Oncol, Barcelona, Spain

[6] Hosp Univ Virgen de la Victoria, Radiat Oncol, Malaga, Spain

[7] Hosp Univ La Paz, Radiat Oncol, Madrid, Spain

[8] Inst Catala Oncol, Radiat Oncol, Badalona, Spain

[9] Inst Catala Oncol, Med Oncol, Badalona, Spain

[10] Hosp Univ Miguel Serves, Radiat Oncol, Zaragoza, Spain

[11] Hosp Univ Vall dHebro, Radiat Oncol, Barcelona, Spain

[12] Hosp Univ Santiagos de Compostela, Radiat Oncol, Santiago De Compostela, Spain

[13] Hosp Univ San Carlos, Radiat Oncol, Madrid, Spain

[14] Hosp Santa Tecla, Med Oncol, Tarragona, Spain

[15] Spherium Biomed, Invest, Barcelona, Spain

来源：

RADIOTHERAPY AND ONCOLOGY | 2019年 / 132卷

关键词：

D O I：

10.1016/S0167-8140(19)30195-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD-029

引用

页码：16 / 17

页数：2

共 50 条

[41] MICROVASCULAR INVASION IN CANCER OF THE ORAL CAVITY AND OROPHARYNX
CLOSE, LG
BURNS, DK
REISCH, J
SCHAEFER, SD
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1987, 113 (11) : 1191 - 1195
[42] Epidemiology of cancer from the oral cavity and oropharynx
Lambert, Rene
Sauvaget, Catherine
Cancela, Marianna de Camargo
Sankaranarayanan, Rengaswamy
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 23 (08) : 633 - 641
[43] CANCERS OF THE ORAL CAVITY AND OROPHARYNX - ECONOMIC COST
NIZRI, D
PATHOLOGIE BIOLOGIE, 1994, 42 (10): : 1042 - 1043
[44] CANCERS OF THE ORAL CAVITY AND OROPHARYNX - ADVANCES IN THERAPY
BERTRAND, JC
PATHOLOGIE BIOLOGIE, 1994, 42 (10): : 1040 - 1041
[45] Malignant tumours of the oral cavity and oropharynx: staging
Youssefzadeh, S
Pamberger, P
Baumgartner, W
Becherer, A
Wachter, S
Burian, M
RADIOLOGE, 1999, 39 (07): : 513 - 524
[46] EVALUATION OF 121 CARCINOMAS OF THE ORAL CAVITY AND OROPHARYNX
WEIDENBECHER
HNO, 1981, 29 (07) : 253 - 253
[47] SURGICAL PATHOLOGY OF CANCER OF THE ORAL CAVITY AND OROPHARYNX
BRENNAN, CT
SESSIONS, DG
SPITZNAGEL, EL
HARVEY, JE
LARYNGOSCOPE, 1991, 101 (11): : 1175 - 1197
[48] Treatment of carcinoma of the oral cavity and oropharynx in Kyrgyzstan
Jemuratov, MA
Shaimbetov, BO
Toktosunov, AT
Yuldashev, IM
ORAL ONCOLOGY, VOL V, 1997, : 310 - 312
[49] MuciLight trial: phase 2 of LED photobiomodulation for treatment of mucositis in oral cavity or oropharyngeal cancer.
Liem, Xavier
Maiezza, Sophie
Wallet, Jennifer
Lals, Severine
Darrou, Marriane
Vanseymortier, Marie
Belot-Cheval, Veronique
Felin, Arnaud
Le Deley, Marie-Cecile
Mirabel, Xavier
RADIOTHERAPY AND ONCOLOGY, 2024, 192 : S274 - S275
[50] Phase II investigational oral drugs for the treatment of radio/chemotherapy induced oral mucositis
Soni, Stephen T.
Villa, Alessandro
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (02) : 147 - 154

← 1 2 3 4 5 →